Cantor Fitzgerald restated their overweight rating on shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) in a report released on Tuesday. Cantor Fitzgerald also issued estimates for Paratek Pharmaceuticals’ FY2017 earnings at ($3.42) EPS and FY2018 earnings at ($2.59) EPS.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday. BidaskClub lowered shares of Paratek Pharmaceuticals from a buy rating to a hold rating in a report on Friday, August 4th. Raymond James Financial, Inc. assumed coverage on shares of Paratek Pharmaceuticals in a report on Thursday, May 18th. They issued a strong-buy rating and a $36.00 price target on the stock. Finally, HC Wainwright boosted their price target on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a buy rating in a report on Tuesday, July 18th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Paratek Pharmaceuticals currently has an average rating of Buy and a consensus price target of $37.44.
Paratek Pharmaceuticals (PRTK) opened at 19.80 on Tuesday. The firm’s 50-day moving average is $22.39 and its 200 day moving average is $19.95. The firm’s market capitalization is $549.67 million. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $26.10.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million during the quarter, compared to the consensus estimate of $7.50 million.
TRADEMARK VIOLATION WARNING: “Paratek Pharmaceuticals, Inc. (PRTK) Rating Reiterated by Cantor Fitzgerald” was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/08/12/paratek-pharmaceuticals-inc-prtk-rating-reiterated-by-cantor-fitzgerald.html.
In other news, VP Adam Woodrow sold 3,800 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total value of $89,604.00. Following the sale, the vice president now owns 69,500 shares of the company’s stock, valued at approximately $1,638,810. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Evan Loh sold 4,351 shares of the company’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $102,596.58. Following the completion of the sale, the chief operating officer now directly owns 112,783 shares in the company, valued at approximately $2,659,423.14. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,960 shares of company stock worth $524,342. 4.90% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in Paratek Pharmaceuticals by 44.0% in the second quarter. Renaissance Technologies LLC now owns 596,749 shares of the specialty pharmaceutical company’s stock valued at $14,382,000 after buying an additional 182,236 shares during the last quarter. EAM Investors LLC purchased a new stake in Paratek Pharmaceuticals during the second quarter valued at $3,471,000. Parametric Portfolio Associates LLC purchased a new stake in Paratek Pharmaceuticals during the second quarter valued at $1,752,000. Quantbot Technologies LP purchased a new stake in Paratek Pharmaceuticals during the second quarter valued at $172,000. Finally, Vanguard Group Inc. raised its stake in Paratek Pharmaceuticals by 19.8% in the second quarter. Vanguard Group Inc. now owns 867,616 shares of the specialty pharmaceutical company’s stock valued at $20,909,000 after buying an additional 143,316 shares during the last quarter. 77.36% of the stock is currently owned by institutional investors and hedge funds.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
What are top analysts saying about Paratek Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Paratek Pharmaceuticals Inc. and related companies.